Physician profile
Michel Daly
NPI 1417719824
$2,348.93
in general payments reported to CMS, 2019-2025
9 companies · $706 in 2025
The $706 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,643 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,011 · Travel and Lodging: $238 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,010.93 |
| Travel and Lodging | $238.01 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Silk Road Medical, INC. | $1,308.35 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Boston Scientific Corporation | $657.20 | 2024-2025 | General - Vascular Intervention, Enroute Transcarotid Neuroprotection System, Enroute .014" Guidewire |
| Astrazeneca Pharmaceuticals LP | $202.25 | 2024 | Lynparza |
| Novartis Pharmaceuticals Corporation | $55.93 | 2024-2025 | |
| Solventum Corporation | $49.65 | 2025 | Prevena, V.A.C.Ulta |
| Shockwave Medical, INC | $22.71 | 2025 | |
| Convatec INC. | $20.47 | 2024 | |
| Smith+Nephew, INC. | $18.23 | 2024 | Pico 14 |
| Artivion, INC. | $14.14 | 2024 | Vascular |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michel Daly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.